An encouraging research programme led by Prof. Sizonenko and Dr Veraldi

The aim of the project is to evaluate the effect of treatment with a heparanase-inhibiting polysaccharide on the MPS III A (Sanfilippo disease) mouse model. This approach, combined with encapsulating the treatment in lipid nanoparticles, is anticipated to increase the bioavailability of the treatment in the brain. Results are anticipated in Spring 2024.

Building on the positive outcomes already achieved by this research programme, a patent application is underway in multiple countries, which is highly promising.